The effect of EGF-Pathway Targeted Immunization (EGF-PTI) on STAT3 and cancer stem cells in EGFR mutant NSCLC cells

The Epidermal Growth Factor Receptor (EGFR) signaling system is frequently unbalanced in non-small-cell lung cancer (NSCLC) and the ligand Epidermal Growth Factor (EGF) could be an attractive target. EGFR tyrosine kinase inhibitors (TKI) are a standard treatment in EGFR mutated tumors but resistance invariably appears due to various mechanisms, such as the secondary mutation p.T790M or the activation of alternative pathways (MET, AXL). We have assayed the antibodies raised by a “cancer vaccine” against human EGF that block EGF-EGFR interaction. This “cancer vaccine“ has been tested successfully in an unselected population in a Phase III clinical trial.